Novartis’ Owen Wallace Joins Fulcrum Tx as Chief Scientific Officer

Xconomy Boston — 

Owen Wallace is leaving Novartis (NYSE: NVS) to become chief scientific officer of Cambridge, MA-based Fulcrum Therapeutics. At Novartis, Wallace was head of the company’s global discovery chemistry division. His experience also includes positions at Eli Lilly (NYSE: LLY) and Bristol-Myers Squibb (NYSE: BMY). Fulcrum aims to treat treat genetic conditions by developing drugs that control the “on and off switches” of disease genes.